Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.
Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies), lack of an optimal biomarker is one of the main challenges to clinical trial success. This represents a huge loss for both industry and the advance of medicine.
LevitasBio will present how single-cell RNA sequencing has progressed the field of drug discovery and how upstream sample preparation methods that preserve cells in their native state is critical in identifying relevant biomarkers for drug discovery and development.
Join DDW for this free event, Broadening the horizon of drug discovery: use of unperturbed, native state cells to uncover true biological targets at single-cell level, which is supported by LevitasBio. Expert Dr Camila Egidio, PhD, Sr Director, Application Development, LevitasBio will present the event.
The event will take place on December 14, 2022 at 4PM GMT, 8AM PT.
What you will learn:
- Overview: Relevance of single-cell RNA sequencing in your drug discovery toolkit
- Sample prep: Obstacles that stand in the way of precise molecular signatures and lead to misguided biomarker identification
- A better way: Using magnetic separation of viable cells present in low quality samples for downstream biomarker discovery
Who should register:
- Drug discovery researchers and single-cell researchers
